<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365077">
  <stage>Registered</stage>
  <submitdate>1/10/2013</submitdate>
  <approvaldate>1/10/2013</approvaldate>
  <actrnumber>ACTRN12613001097730</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers</studytitle>
    <scientifictitle>Evaluation of the Pharmacokinetics of IPX237 Formulations in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An single-center, open-label, randomized, single-dose, 4-sequence, 4-treatment crossover study with at least 5 days of washout between dosing in each treatment period. Subjects will receive the following investigational treatments under fasted conditions in a randomized sequence: Treatment A: 1 capsule of IPX237-C0001 30 mg Treatment B: 1 capsule of IPX237-C0002 30 mg Treatment C: sublingual paste of IPX237-L0001 30 mg Treatment D: 15 mg esketamine (free base equivalent) infused IV over 40 minutes Postdose: The subject should be evaluated at 32 hours postdose to determine that they are medically stable. The subject should be driven home by a responsible adult </interventions>
    <comparator>Treatment D: 15 mg esketamine (free base equivalent) infused IV over 40 minutes
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics</outcome>
      <timepoint>During each treatment period, blood samples will be collected for measurement of esketamine and potential metabolites in plasma at the following times:  within 60 minutes predose, and postdose at 10, 20, 30, 40, and 50 minutes and  1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours. Saliva samples will be collected at Check-in, and postdose at 40 minutes, 6 hours, 12 hours, and 24 hours for potential analysis of esketamine and its metabolites.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>Three serial 12-lead electrocardiograms (ECG), clinical laboratory tests, vital signs, adverse events (AEs), and concomitant medications will be evaluated over the course of the study. Physical examinations will be performed at Screening and at Study Exit. Three serial ECGs will be evaluated in each treatment period at Screening, predose, and at 45 minutes, 8, and 24 hours postdose. Telemetry will be obtained from 1 hour predose to 8 hours postdose. Vital signs will be measured in each period as specified. Psychiatric effects and dissociative symptoms will be assessed at specified times postdose by the Brief Psychiatric Rating Scale (BPRS) and dissociative symptoms will be gauged by the Clinician-Administered Dissociative States Rating Scale (CADSS). </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers between the ages of 18 and 55 years of age inclusive and weighing at least 60 kg at the time of informed consent. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Presence of a clinically significant disorder, including acute or chronic infections or a malignant neoplasm and/or involving disease in one or more of these organ systems: cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, dermatologic, hepatic, reproductive, endocrine, or neurologic/psychiatric, as determined by clinical investigators.	
History of psychosis in self or family.  
History of or clinical signs of glaucoma.  
History of or clinical signs of any form of epilepsy or seizures  

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>9/12/2013</anticipatedstartdate>
    <actualstartdate>9/12/2013</actualstartdate>
    <anticipatedenddate>25/01/2014</anticipatedenddate>
    <actualenddate>25/01/2014</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Impax Pharmaceuticals, A Division of Impax Laboratories, Inc.</primarysponsorname>
    <primarysponsoraddress>31047 Genstar Road, 
Hayward, CA 94544</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Impax Laboratories, Inc.</fundingname>
      <fundingaddress>30831 Huntwood Avenue
Hayward, CA94544</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To characterize the pharmacokinetics (PK) of esketamine hydrochloride from 2 oral and 1 sublingual formulations of IPX237 compared to that from intravenous esketamine hydrochloride. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>71 Anzac Highway
Ashford, SA 5035
</ethicaddress>
      <ethicapprovaldate>20/11/2013</ethicapprovaldate>
      <hrec>2013-10-538</hrec>
      <ethicsubmitdate>9/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sepehr Shakib</name>
      <address>CMAX, a division of IDT Australia  Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000
</address>
      <phone>+61 08 8222-4638</phone>
      <fax />
      <email>sepehr.shakib@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Cmax</name>
      <address>Level 5 East Wing Royal Adelaide Hospital
North Terrace
Adelaide  SA  5000 
</address>
      <phone>1800 150 433</phone>
      <fax />
      <email>cmax@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sepehr Shakib</name>
      <address>CMAX, a division of IDT Australia  Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000
</address>
      <phone>+61 08 8222-4638</phone>
      <fax />
      <email>sepehr.shakib@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>